

Soverini S, Bavaro L, De Benedittis C, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. *Blood*. 2020;135(8):534-541.

In the author affiliations on page 534, the affiliation for author Stefano Aldo Pileri (affiliation 29) should read "Istituto Europeo di Oncologia-IRCCS, Milan, Italy" instead of "Division of Haematopathology, European Institute of Oncology, Milan, Italy." The error has been corrected in the online version of the article.

DOI 10.1182/blood.2022015379

© 2022 by The American Society of Hematology

Tarlock K, Lamble AJ, Wang Y-C, et al. *CEBPA*-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. *Blood*. 2021;138(13):1137-1147.

In Figure 5 on page 1145, the numbers of patients in the *CEBPA*⁺/*GATA2*⁺ and *CEBPA*⁺/*CSF3R*⁺ molecular cohorts are reversed. In Figure 5A and C, the curves should be labeled as 23 patients with *CEBPA*⁺/*GATA2*⁺ and 13 patients with *CEBPA*⁺/*CSF3R*⁺. In Figure 5B, the curves should be labeled as 20 patients with *CEBPA*⁺/*GATA2*⁺ and 13 patients with *CEBPA*⁺/*CSF3R*⁺. The correct numbers of patients were used for analysis. The corrected Figure 5 is shown below.




Figure 5. Outcomes of *CEBPA*-mutant patients according to co-occurring *CSF3R* and *GATA2* mutational status. (A) EFS of dual *CEBPA*⁺/*CSF3R*⁺ mutant patients compared with those with dual *CEBPA*⁺/*GATA2*⁺ and those with a *CEBPA*⁺ mutation and neither *CSF3R* nor *GATA2*; (B) RR of dual *CEBPA*⁺/*CSF3R*⁺ mutant patients compared with dual *CEBPA*⁺/*GATA2*⁺ and patients with a *CEBPA*⁺ mutation and neither *CSF3R* nor *GATA2*; (C) OS of dual *CEBPA*⁺/*CSF3R*⁺ mutant patients compared with dual *CEBPA*⁺/*GATA2*⁺ and patients with a *CEBPA*⁺ mutation and neither *CSF3R* nor *GATA2*.